221 related articles for article (PubMed ID: 21471526)
1. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.
Haefliger S; Klebig C; Schaubitzer K; Schardt J; Timchenko N; Mueller BU; Pabst T
Blood; 2011 Jun; 117(22):5931-40. PubMed ID: 21471526
[TBL] [Abstract][Full Text] [Related]
2. Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia.
Schardt JA; Eyholzer M; Timchenko NA; Mueller BU; Pabst T
J Cell Mol Med; 2010 Jun; 14(6B):1509-19. PubMed ID: 19659458
[TBL] [Abstract][Full Text] [Related]
3. Activation of the unfolded protein response in human acute myeloid leukemia.
Schardt JA; Mueller BU; Pabst T
Methods Enzymol; 2011; 489():227-43. PubMed ID: 21266233
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
5. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations.
Pulikkan JA; Peramangalam PS; Dengler V; Ho PA; Preudhomme C; Meshinchi S; Christopeit M; Nibourel O; Müller-Tidow C; Bohlander SK; Tenen DG; Behre G
Blood; 2010 Dec; 116(25):5638-49. PubMed ID: 20889924
[TBL] [Abstract][Full Text] [Related]
6. PU.1 and CEBPA expression in acute myeloid leukemia.
D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
[TBL] [Abstract][Full Text] [Related]
7. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia.
Schardt JA; Weber D; Eyholzer M; Mueller BU; Pabst T
Clin Cancer Res; 2009 Jun; 15(11):3834-41. PubMed ID: 19470730
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
[TBL] [Abstract][Full Text] [Related]
9. The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients.
Mans S; Banz Y; Mueller BU; Pabst T
Blood; 2012 Sep; 120(13):2690-9. PubMed ID: 22915645
[TBL] [Abstract][Full Text] [Related]
10. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.
Helbling D; Mueller BU; Timchenko NA; Hagemeijer A; Jotterand M; Meyer-Monard S; Lister A; Rowley JD; Huegli B; Fey MF; Pabst T
Proc Natl Acad Sci U S A; 2004 Sep; 101(36):13312-7. PubMed ID: 15326310
[TBL] [Abstract][Full Text] [Related]
11. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen JS; Laursen LG; Schuster MB; Pundhir S; Schoof E; Ge Y; d'Altri T; Vitting-Seerup K; Rapin N; Gentil C; Jendholm J; Theilgaard-Mönch K; Reckzeh K; Bullinger L; Döhner K; Hokland P; Fitzgibbon J; Porse BT
Sci Adv; 2019 Jul; 5(7):eaaw4304. PubMed ID: 31309149
[TBL] [Abstract][Full Text] [Related]
12. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
13. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).
Helbling D; Mueller BU; Timchenko NA; Schardt J; Eyer M; Betts DR; Jotterand M; Meyer-Monard S; Fey MF; Pabst T
Blood; 2005 Aug; 106(4):1369-75. PubMed ID: 15855281
[TBL] [Abstract][Full Text] [Related]
14. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract][Full Text] [Related]
15. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
16. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
17. PDI is an essential redox-sensitive activator of PERK during the unfolded protein response (UPR).
Kranz P; Neumann F; Wolf A; Classen F; Pompsch M; Ocklenburg T; Baumann J; Janke K; Baumann M; Goepelt K; Riffkin H; Metzen E; Brockmeier U
Cell Death Dis; 2017 Aug; 8(8):e2986. PubMed ID: 28796255
[TBL] [Abstract][Full Text] [Related]
18. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
Wang LM; Xiao HW; Huang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
[TBL] [Abstract][Full Text] [Related]
19. The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.
Federzoni EA; Humbert M; Valk PJ; Behre G; Leibundgut EO; Torbett BE; Fey MF; Tschan MP
Br J Haematol; 2013 Mar; 160(6):855-9. PubMed ID: 23252456
[No Abstract] [Full Text] [Related]
20. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]